17,261 trials
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Cumulative Incidence of CMV at 100 Days — 25.1; 13.8 cases per 100 persons
Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure — -2.30; -2.18 mmHg — p=0.89
Nutrient Deficiency · Pregnancy Related
Primary: Change in Maternal Macular Carotenoid Levels From Enrollment to Birth of Infant — 12244; 7343 unitless
Gallbladder Carcinoma · Metastatic Cholangiocarcinoma · Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Progression Free Survival (PFS) — 0; 3; 39; 35 Participants — p=0.027
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 3; 6; 4; 6 Participants
Chemo-radiation Induced Nausea and Vomiting
Primary: Complete Response (CR) Rate as Measured by Antiemesis Tool (MAT) — 0.5717; 0.7368 proportion of participants — p=0.2734
Prostate Cancer
Primary: Late Grade ≥ 3 Gastrointestinal (GI) and Genitourinary (GU) Toxicity of Interest, Using the CTCAE v4.0 — 1; 0 Participants
Pancreatic Cancer
Primary: Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1) — 0; 2 Participants
Rotavirus Infections
Primary: Number of Participants With a Cumulative Anti Rotavirus Serum Immunoglobulin A (IgA) Response (≥3 Fold Increase From Baseline) in Neonatal Vaccine Schedule at High Mid…
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Complete Response (CR) Rate — 0; 36 percent of participants
Post Traumatic Stress Disorder · Relational Problems
Primary: Couples Satisfaction Inventory-32 — 103.6; 87.30 score on a scale
Glomerulosclerosis, Focal Segmental
Primary: Percent Change From Baseline in UPCR — -47.7; -47.5; -47.6 percent change
Epidermolysis Bullosa Dystrophica · Epidermolysis Bullosa
Primary: Number of Wounds by Healing Category Per Investigator Visual Assessment — 35; 5; 2; 28 wounds
Hepatocellular Carcinoma · Resectable Hepatocellular Carcinoma
Primary: Safety and Tolerability of Presurgical Nivolumab With or Without Ipilimumab, Defined as the Number of Participants With of Adverse Events. — 13; 14; 0 Participants
ADNP Syndrome
Primary: Number of Participants With an Adverse Event — 9 Participants